Bronchial Chondronecrosis After Proton Beam Therapy Successfully Treated With Hyperbaric Oxygen Therapy Authors: Masataka Hirai, Takamasa Kitajima, SungChul Park, Takehisa Takagi, Ikuko Honda, Yokiko Ohe, Daiki Inoue, Motonari Fukui, Satoshi Marumo Published: 2026 ABSTRACT ABSTRACTAirway chondronecrosis is a rare but serious manifestation of late radiation‐induced toxicity. We report the case of a 67‐year‐old woman with epidermal growth factor receptor mutation‐positive lung adenocarcinoma who developed bronchial chondronecrosis 8 years after proton‐beam therapy (PBT) to the right upper lobe nodule. For 2 years, she was treated for cough‐variant asthma owing to a persistent cough. Chest computed tomography (CT) showed only a subtle irregularity of the right main bronchial wall. Bronchoscopy revealed yellow necrotic deposits in the right main bronchi. Although a conventional forceps biopsy was nondiagnostic, transbronchial lung cryobiopsy (TBLC) obtained cartilage specimens, confirming bronchial chondronecrosis without malignancy. Hyperbaric oxygen therapy (HBOT) (90 sessions in total) led to symptomatic and bronchoscopic improvement. This case highlights that very‐late‐onset airway chondronecrosis following PBT must be considered, even with minimal CT findings. TBLC is a valuable tool for diagnosing submucosal lesions and HBOT appears to be an effective therapy. Introduction Airway chondronecrosis is an uncommon but severe late effect of thoracic irradiation. Most reported cases of tracheal injury occur after high‐dose photon radiotherapy. The interval between irradiation and onset is variable, ranging from several months to years [1]. Radiation‐induced laryngeal chondronecrosis occurs in 1%–5% of patients, whereas the incidence of bronchial chondronecrosis remains unknown because of its rarity [2]. In contrast, proton beam therapy (PBT) is designed to minimise collateral damage via its characteristic Bragg peak energy distribution. Severe airway cartilage injury after PBT has rarely been reported. Additionally, no standard treatment has been established for bronchial chondronecrosis. Here, we present a novel case of bronchial chondronecrosis occurring 8 years after PBT for solitary recurrent lung adenocarcinoma, which was pathologically confirmed using transbronchial lung cryobiopsy (TBLC) and treated with hyperbaric oxygen therapy (HBOT). Case Report A 67‐year‐old woman with epidermal growth factor receptor (EGFR) mutation‐positive lung adenocarcinoma underwent right middle and lower lobectomy, followed by EGFR tyrosine kinase inhibitor (TKI) therapy for postoperative recurrence and achieved long‐term disease control. Three years later, a solitary recurrence in the right upper lobe was treated with PBT (66 Gy (relative biological effectiveness, RBE) in 10 fractions; [RBE] = 1.1) (Figure 1A). PBT dose distribution map and CT scans of the chest before and after hyperbaric oxygen therapy. (A) Dose distribution map showing irradiation of the right main bronchial wall with greater exposure along the posterior wall. (B) CT scan demonstrating a subtle irregularity (red arrow) of the right main bronchus before HBOT. (C) CT scan showing improvement in irregularity after HBOT. CT, computed tomography; HBOT, hyperbaric oxygen therapy; PBT, proton beam therapy. Six years after PBT, she developed a cough that lasted for 2 years. A chest computed tomography (CT) scan demonstrated a subtle irregularity of the posterior wall of the right main bronchus (Figure 1B). Bronchoscopy revealed yellow necrotic deposits in the bronchial mucosa, predominantly along the posterior wall (Figure 2A). Conventional forceps biopsy was nondiagnostic. However, TBLC yielded a larger tissue specimen containing cartilage and histopathological examination confirmed cartilage necrosis without the involvement of malignant tumours, fungal infections, mycobacterial infections, or granulomatous diseases. Airway lesions corresponded to the prior PBT irradiation field. HBOT (100% O2) was performed at 2.0 ATA for 60 min/session, with 15‐min compression and decompression phases (total: 90 min), comprising 30 sessions per course for three courses (90 sessions). Two months after HBOT initiation, the patient reported substantial symptomatic relief, and 1 year after the initiation, her Leicester Cough Questionnaire score improved from 11.2 to 16.6 and cough severity visual analogue scale score decreased from 100 to 20 mm. A follow‐up CT scan demonstrated improvements in the irregularity of the bronchial wall (Figure 1C). Bronchoscopy performed 1 year after HBOT initiation revealed the necrotic deposits' reduction (Figure 2B). The patient was continued on EGFR‐TKI therapy after PBT for local recurrence; however, it was temporarily discontinued during HBOT for bronchial chondronecrosis because of concerns regarding its potential adverse effect on tissue repair. After completion of HBOT, EGFR‐TKI therapy was resumed and continued until the latest follow‐up, and the patient remained disease‐free. Bronchoscopic findings of the right main bronchus before and after hyperbaric oxygen therapy. (A) Yellow necrotic deposits are visible in the bronchial mucosa before HBOT, predominantly along the posterior wall. (B) Follow‐up bronchoscopy demonstrating improvement in mucosal abnormalities after HBOT. HBOT, hyperbaric oxygen therapy. Discussion To our knowledge, this is the first report of bronchial chondronecrosis after PBT that was pathologically confirmed using TBLC and treated with HBOT. Although PBT is generally considered less toxic owing to its Bragg peak distribution than photon radiotherapy, airway cartilage necrosis can still occur as a manifestation of late radiation toxicity. In this patient, the posterior wall of the right main bronchus showed severe abnormalities on CT and bronchoscopy, which closely corresponded to the dose distribution map, suggesting that radiation toxicity was the most likely aetiology. Radiation‐induced obliterative vasculopathy creates a chronic hypoxic, hypovascular and hypocellular tissue environment, rendering the bronchial cartilage susceptible to delayed ischemic injury. Notably, radiation‐induced laryngeal cartilage necrosis has been reported even decades after irradiation, underscoring the complex multifactorial pathogenesis of radionecrosis in avascular cartilage. It is also suggested that EGFR signalling plays an important role in epithelial homeostasis and wound healing. EGFR inhibition can impair epithelial cell proliferation, migration, differentiation and barrier function, leading to mucocutaneous toxicities [3]. In addition, EGFR inhibition may enhance radiation effects through impaired DNA repair [4]. Therefore, EGFR‐TKI therapy may have increased the vulnerability of the irradiated bronchial mucosa and delayed tissue repair, thereby potentially contributing to the development and persistence of bronchial chondronecrosis. From a diagnostic perspective, airway radionecrosis may manifest only as a persistent cough with subtle CT findings, leading to delayed diagnosis. Therefore, a persistent cough after thoracic irradiation warrants detailed imaging and bronchoscopic evaluation to promptly detect these late complications. TBLC was superior to conventional forceps biopsy as it provides larger, artefact‐free specimens that include sufficient cartilage for establishing a histopathological diagnosis, a feature that is rarely reported previously. Medical management modalities for the laryngeal radionecrosis include antibiotics and corticosteroids, and total laryngectomy may be required in severe cases. HBOT is also used as an adjunctive treatment [5]. HBOT promotes radionecrosis healing; however, its efficacy in bronchial chondronecrosis remains less established than that in osteoradionecrosis or laryngeal radionecrosis. The mechanism of HBOT extends beyond tissue hyperoxygenation; intermittent hyperoxia stimulates neovascularisation and enhances tissue repair. Moreover, the amelioration of ischemia, a common pathophysiological mechanism underlying radiation‐induced necrosis, may contribute to the resolution of bronchial cartilage necrosis. Although no standard first‐line treatment has been established for bronchial chondronecrosis, in our case, as there was little evidence of infection or inflammatory exacerbation, we did not administer antibiotics or corticosteroids. Given the effectiveness of HBOT in the laryngeal radionecrosis and high invasiveness of surgery, we administered HBOT as the treatment, which successfully contributed to symptomatic and bronchoscopic improvement. In conclusion, bronchial chondronecrosis can manifest as a late complication of PBT, presenting with only persistent cough and subtle CT changes. TBLC is essential for a definitive diagnosis when conventional biopsy fails. HBOT may result in symptomatic and bronchoscopic improvements. Author Contributions M.H., T.K., I.H., D.I., M.F. and S.M. contributed to clinical data collection, patient management and interpretation of the findings. S.P., Y.O. and T.T. contributed to planning and administration of HBOT, and interpretation of proton beam therapy. All authors critically revised and approved the final manuscript, agreed to be accountable for all aspects of the work and meet the ICMJE authorship criteria. Funding The authors have nothing to report. Consent The authors declare that written informed consent was obtained for the publication of this manuscript and accompanying images using the consent form provided by the Journal. Conflicts of Interest The authors declare no conflicts of interest.